Sjögren’s syndrome (SS) is a progressive autoimmune disease characterized by chronic inflammation and lymphocytic infiltration of the exocrine glands that may occur alone (primary SS) or with a comorbid autoimmune condition (secondary SS). At present, symptomatic therapies to treat dry eyes, dry mouth, or specific extraglandular manifestations are the cornerstone of disease management. Systemic manifestations are most often treated with hydroxychloroquine or, in severe cases, with systemic immunomodulators (e.g., azathioprine, methotrexate). Emerging therapies with disease-modifying potential are now in development for SS, targeting key pathways believed to drive pathological processes in the disease. These putative disease-modifying therapies have the potential to transform the management of SS, although SS has historically proven to be a challenging indication in which to succeed.


  • How large is the SS population and how will its size change over time?
  • How is SSmanaged? Which are the most important drugs and what drives their use?
  • Which unfulfilled clinical needs are most pressing?
  • What pipeline products are most promising, and what sales might they garner in the SS market? What therapies of note are progressing in earlier phases?
  • What are the drivers and constraints in the SS market, and how will the market evolve through 2027?


Niche & Rare Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Disease Landscape & Forecast
    • Commercial Outlook
      • Key Findings
      • Drivers and Constraints
        • What Factors Are Driving Sales in Sjögren's Syndrome?
        • What Factors Are Constraining Sales in Sjögren's Syndrome?
      • Drug-Class-Specific Trends
        • Biologics
    • Forecast
    • Etiology and Pathophysiology
      • Disease Overview
      • Clinical Presentation
        • Autoimmune Diseases Commonly Associated with Sjögren's Syndrome
        • Increased Risk of Lymphoma in Sjögren's Syndrome Patients
        • Sjögren's Syndrome Disease Activity Indices
      • Etiology
      • Pathophysiology
        • Dysregulation of Immune Function
      • Key Pathways and Drug Targets
    • Epidemiology
      • Key Findings
      • Epidemiology Populations
        • Diagnosed Prevalent Cases
        • Drug-Treated Cases of Sjögren's Syndrome
    • Current Treatment
      • Key Findings
      • Diagnosis
        • Treatment Providers and Referral Patterns
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • Muscarinic Receptor Agonists
        • Anti-Inflammatory Ophthalmic Drugs
        • Antimalarials
        • Conventional Systemic Therapies
        • Biologics
      • Medical Practice
        • Overview
        • Treatment Guidelines
        • Region-Specific Treatment Practices
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in Sjögren's Syndrome
    • Emerging Therapies
      • Key Findings
      • Key Emerging Therapies
        • Notable Developments Among Key Emerging Therapies for Sjögren's Syndrome
        • CD40 Inhibitors
        • Selective Costimulation Inhibitors
        • Ribonuclease Fc Fusion Proteins
        • B-cell Activation Factor Inhibitors
        • Tyrosine Kinase Inhibitors
      • Early-Phase Pipeline Analysis
        • Notable Developments in the Early-Phase Pipeline for Sjögren's Syndrome
      • Patient Registries
        • Patient Organizations
    • Access & Reimbursement Overview
      • Looking for More?
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug-Specific Assumptions
      • Bottom-Up Forecast Assumptions
        • General Sources of Data
        • General Statements About Pricing
        • Dosing, Days of Therapy, and Compliance
        • Biosimilar Erosion
        • Out-Year Forecasting
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Bibliography

Author(s): Michael Breen, PhD; Sunali D. Goonesekera, SM

Michael is a business insights analyst on the Infectious, Niche, and Rare Diseases team. He has authored reports on cystic fibrosis, nonalcoholic steatohepatitis, vaccines, and  respiratory syncytial virus, and will author a report on cytomegalovirus. He also provides coverage for Decision Resources’ Company & Drug Insights covering anti-infectives, vaccines, and transplant therapy areas. Michael received his Bachelor’s degree from Hunter College with a dual major in biology and biochemistry. He received his in biochemistry from Boston University School of Medicine. His postdoctoral research was carried out at Brigham and Women’s Hospital/Harvard Medical School, with a focus on identifying novel pathways regulating thermogenesis in search of a therapeutic for obesity and diabetes.

Sunali Goonesekera is an Associate Epidemiologist at Decision Resources Group. Sunali holds a Master’s degree in Epidemiology from the Harvard School of Public Health and a in Biology (Honors) from Dartmouth College. Prior to joining Decision Resources Group, Sunali conducted epidemiological research and lead authored two manuscripts on racial/ethnic disparities in metabolic diseases at the New England Research Institutes. She has contributed to multiple publications in peer-reviewed journals in epidemiology and in the biological sciences.

Related Reports

Sjogren's Syndrome | Current Treatment | Detailed, Expanded Analysis (US)

The primary goals of treatment of Sjögren’s syndrome (SS) are to relieve the hallmark sicca symptoms and minimize the impact and progression of...

View Details

Sjogren's Syndrome | Unmet Need | Detailed, Expanded Analysis (US & EU) Primary Sjogren's Syndrome

No disease-modifying therapies are approved to treat primary Sjögren’s syndrome (pSS), a progressive, autoimmune disease characterized b...

View Details